posted on 2017-05-08, 00:00authored byChangsun Kang, Sian Gwon, ChulGyu Song, Peter M. Kang, Seong-Cheol Park, Jongho Jeon, Do Won Hwang, Dongwon Lee
A thrombus (blood clot) is formed
in injured vessels to maintain the integrity of vasculature. However,
obstruction of blood vessels by thrombosis slows blood flow, leading
to death of tissues fed by the artery and is the main culprit of various
life-threatening cardiovascular diseases. Herein, we report a rationally
designed nanomedicine that could specifically image obstructed vessels
and inhibit thrombus formation. On the basis of the physicochemical
and biological characteristics of thrombi such as an abundance of
fibrin and an elevated level of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), we developed a fibrin-targeted imaging and antithrombotic
nanomedicine, termed FTIAN, as a theranostic system for obstructive
thrombosis. FTIAN inhibited the generation of H<sub>2</sub>O<sub>2</sub> and suppressed the expression of tumor necrosis factor-alpha (TNF-α)
and soluble CD40 ligand (sCD40L) in activated platelets, demonstrating
its intrinsic antioxidant, anti-inflammatory, and antiplatelet activity.
In a mouse model of ferric chloride (FeCl<sub>3</sub>)-induced carotid
thrombosis, FTIAN specifically targeted the obstructive thrombus and
significantly enhanced the fluorescence/photoacoustic signal. When
loaded with the antiplatelet drug tirofiban, FTIAN remarkably suppressed
thrombus formation. Given its thrombus-specific imaging along with
excellent therapeutic activities, FTIAN offers tremendous translational
potential as a nanotheranostic agent for obstructive thrombosis.